Autopsy report · NCT01345669
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Cause of deathNo reason given
Life of this trial
- Registered 6 months before it started.
- Ran for about 4 years 11 months before it stopped.
- 617 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Conditions
- Head and Neck Neoplasms
- Interventions
- Placebo; Afatinib
- Participants
- 617
- Sites
- 162
- Countries
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Egypt, Finland, France and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.